AmorChem invests in potential cancer-fighting technology developed at McGill
AmorChem, an early-stage life sciences fund managed by Canadian venture capital firm GeneChem, has invested in a project focused on the role of the IGF axis in cancer development, invasion and metastasis that is being conducted by McGill University professor Dr. Pnina Brodt in collaboration with the National Research Council of Canada. The investment, which was made in partnership with Québec commercialization and technology transfer hub MSBi Valorisation, is intended to bring the project's novel cancer-treating innovation closer to clinical applications. AmorChem was in Nov. 2013 profiled by peHUB Canada in a feature article about Univalor and new startup opportunities in Québec.
21 January 2014•5 mins read
